Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus MICROZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus MICROZIDE.
ANHYDRON vs MICROZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic